From Nasdaq Inc.:

their targets, which promises to make Entrada’s approach a game-changer in the biopharma field.

In its most recent financial release, Q4, Entrada reported total operating revenues of $30.1 million, up an impressive 74% year-over-year. The company’s net loss, at 27 cents per share, was slightly greater than the 25-cent loss forecast, but investors were pleased to see the robust revenue growth. The company’s cash position, of $327 million, gives it the resources to secure its clinical development program through the next decade, and to bring its drugs through the clinical trial phases to regulatory approval. Following the earnings report, Oppenheimer’s Leland Gershell upgraded his stance on TRDA from Neutral to Outperform (Buy), setting a price target of $34 that implies an upside of 61% for the coming year. (To watch Gershell’s track record, click here)The analyst consensus on TRDA is a Moderate Buy, based on 3 Buys and 1 Hold set in recent weeks. The stock’s $27.25 average price target suggests a 26% upside from the $21.65 current trading price. (See TRDA stock forecast)



Read more: ‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks